We conducted a feasibility study to determine the safety and efficacy of liposome-encapsulated doxorubicin (Myocet) and vinorelbine in previously treated metastatic breast cancer patients.
Patients and methods
Liposome-encapsulated doxorubicin (30 mg/m2) plus vinorelbine (25 mg/m2) on days 1 and 8, every 3 weeks were given until disease progression, sever toxicity or up to 9 cycles. All patients underwent tumor assessment before enrollment. Patients with a life expectancy longer than 3 months and measurable or assessable disease were eligible.
Results
Twenty-one patients were included. Median number of treatment cycles was 5 (range, 3–9). No complete response was obtained. Stable disease and/or partial response was obtained in 9 patients. Fifteen patients experienced grade 3–4 leukopenia. There was no significant decline in cardiac function. Non-hematological toxicity was tolerable (grade 1–2).
Conclusions
The association of doxorubicin and vinorelbine has been shown to be feasible in previously treated advanced breast cancer patients. Its efficacy should be tested as first-line therapy in metastatic patients with cardiac co-morbidities.
ClarkG.M., SledgeG.W.Jr., OsborneC.K., McGuireW.L.: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol, 5: 55–61, 1987.
2.
GreenbergP.A., HortobagyiG.N., SmithT.L., ZieglerL.D., FryeD.K., BudzarA.U.: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol, 14: 2197–2205, 1996.
3.
CowanJ.D., NeidhartJ., McClureS., ColtmanC.A.Jr., GumbartC., MartinoS., HutchiusL.F., StephensR.L., VanghanC.B., OsborneC.K.: Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J Natl Cancer Inst, 83: 1077–1084. 1991.
4.
HendersonI.C., AllegraJ.C., WoodcockT., WolffS., BryanS., CartwrightK., DukartG., HenryD.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol, 7: 560–571, 1987.
5.
RybergM., NielsenD., SkovsgaardT., HansenJ., JensenB.V., DombernowskyP.: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol, 16: 3502–3508, 1998.
6.
DoroshowJ.H.: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res, 43: 460–472, 1983.
7.
MyersC.E., McGuireW.P., LissR.H., IfrimI., GrotzingerK., YoungR.C.: Adryamicin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science, 197: 165–167, 1977.
8.
LaunchburyA.P., HabboubiN.: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev, 19: 197–228, 1993.
9.
BatistG., BartonJ., ChaikinP., SwensonC., WellesL.: Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother, 3: 1739–1751, 2003.
KanterP.M., BullardG.A., GinsbergR.A., PilkiewiczF.G., MayerL.D., CullisP.R., PavelicZ.P.: Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In vivo, 7: 17–26, 1993.
12.
BatistG., RamakrishnanG., Sekhar RaoC.: Reduced cardiotoxicity and preserved antitumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol, 19: 1444–1454, 2001.
13.
HarrisL., BatistG., BeltR., RoviraD., NavariR., AzamiaN., WellesL., WinerE., TLC D-99 Study Group: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94: 25–36, 2002.
14.
FumoleauP., DelgadoF.M., DelozierT., MonnierA., Gil DelgadoM.A., KerbratP., Garcia-GiroltE., KeilingR., NamerM., ClosonM.T.: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol, 11: 1245–1252, 1993.
15.
Garcia-CondeJ., LluchA., MartinM.: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol, 5: 854–857, 1994.
16.
RomeroA., RabinovichM.G., VallejoC.T., PerezJ.E., RodriguezR., CuevasM.A., MacchiavelliM., LacavaJ.A., LanghiM., Romero AcünaL.: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol, 12: 336–341, 1994.
17.
TwelvesC.J., DobbsN.A., CurnowA., ColemanR.E., StewartA.L., TyrrelC.J., CanneyP., RubensR.D.: A phase II multicenter, UK study of vinorelbine in advanced breast cancer. Br J Cancer, 70: 990–993, 1994.
18.
WeberB.L., VogelC., JonesS., HarveyH., HutchinsL., BigleyJ., HolnekerJ.: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol, 13: 2722–2730, 1995.
19.
BlomqvistC., HietanenP., TeerenhoviL., RissanenP.: Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer, 31A: 2406–2408, 1995.
20.
BaldiniE., TibaldiC., ChiavacciF., Di LietoM., FiorettoL., GiallombardoA., TavianiR., GhezziP., BologniniA., ConteP.: Epirubicin/vinorelbine as first-line therapy in metastatic breast cancer. Breast Cancer Res Treat, 49: 129–134, 1998.
21.
EjlertsenB., HenningT., MouridsenT., LangkjerS.T., AndersenJ., SjöströmJ., KyaerM., Scandinavian Breast Group Trial: Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol, 22: 2313–2320, 2004.
22.
EzzatA., MotawyS., BerryJ.: Pilot study of navelbine and epirubicin for the treatment of inoperable locally advanced and metastatic breast cancer. Ann Oncol, 7: 31 (abstr), 1996.
23.
NorrisB., PritchardK.I., JamesK., MylesJ., BennetK., MarlinS., SkillingsJ., FindlayB., VandenbergT., GossP., La FuilleJ., RudinskasL., LoftersW., TrudeauM., OsobaD., RodgersA.: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA 8. J Clin Oncol, 18: 2385–2394, 2000.
24.
TsuchidaY., TherasseP.: Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol, 37: 1–3, 2001.
25.
World Health Organization: WHO Handbook for reporting results of cancer treatment, pp 1–45, Geneva, Switzerland, 1979.
